Related Experiment Video
Updated: Jul 8, 2025
Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay
Published on: October 18, 2016
Epigallocatechin Gallate Modulates Microglia Phenotype to Suppress Pro-inflammatory Signalling Cues and Inhibit
Philip Regan1, Katriona L Hole1, Julia Sero1
1Department of Life Sciences, University of Bath, Bath, UK.
Abstract:
Microglia are crucial players in the pathogenesis of late-onset Alzheimer's disease (AD), with evidence for both deleterious and beneficial effects. Identifying interventions to modulate microglial responsiveness, promote amyloid β (Aβ) clearance, disrupt plaque formation, or dampen excessive inflammation has therapeutic potential. Bioavailable flavonoids, such as the flavan 3-ols, are of interest due to their antioxidant, metal chelating, signalling, and anti-inflammatory potential. Primary microglia were treated with a series of structurally related flavanol 3-ols to assess effects on phagocytosis, cytokine release, and transcriptional responses by RNA sequencing. Data indicated that the extent of hydroxylation and the presence of the galloyl moiety were strong determinants of flavan 3-ol activity. Epigallocatechin gallate (EGCG) was the most effective flavan-3-ol tested and strongly inhibited phagocytosis of Aβ independent of any metal chelating properties, suggesting a more direct modulation of microglia responsiveness. EGCG was broadly anti-inflammatory, reducing cytokine release and downregulating transcription, particularly of components of the microglia extracellular matrix such as MMP3 and SerpinB2. Collectively, this brings new insight into the actions of flavonoids on microglial responsiveness with potential implications for the therapeutic use of EGCG and structurally related flavanol-3-ols in AD.
Insights
Epigallocatechin gallate (EGCG) modulates microglia, key cells in Alzheimer's disease (AD). This flavanol inhibits amyloid-beta (Aβ) phagocytosis and reduces inflammation, offering therapeutic potential for AD.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Microglia play a critical role in Alzheimer's disease (AD) pathogenesis, exhibiting both beneficial and detrimental functions.
- Modulating microglial activity is a potential therapeutic strategy for AD, targeting amyloid-beta (Aβ) clearance, plaque formation, and neuroinflammation.
- Flavan-3-ols, a class of bioavailable flavonoids, possess antioxidant, metal-chelating, signaling, and anti-inflammatory properties of interest for AD intervention.
Purpose of the Study:
- To investigate the effects of structurally related flavan-3-ols on primary microglia functions.
- To assess the impact of these compounds on phagocytosis, cytokine release, and transcriptional profiles.
- To identify key structural features of flavan-3-ols that determine their bioactivity relevant to AD.
Main Methods:
- Primary microglia were treated with various flavan-3-ols.
- Assays were performed to measure phagocytosis of amyloid-beta (Aβ) and cytokine release.
- RNA sequencing was utilized to analyze transcriptional responses.
Main Results:
- The degree of hydroxylation and the presence of a galloyl group significantly influenced flavan-3-ol activity.
- Epigallocatechin gallate (EGCG) demonstrated the highest efficacy, notably inhibiting Aβ phagocytosis independently of metal chelation.
- EGCG exhibited broad anti-inflammatory effects, reducing cytokine release and downregulating key microglial genes like MMP3 and SerpinB2.
Conclusions:
- Flavan-3-ol activity is strongly dependent on specific structural features, such as hydroxylation and the galloyl moiety.
- Epigallocatechin gallate (EGCG) directly modulates microglial responsiveness, inhibiting Aβ phagocytosis and exerting anti-inflammatory effects.
- These findings suggest potential therapeutic applications for EGCG and related flavan-3-ols in managing Alzheimer's disease.
